➤ Treat a first recurrence with a standard 10-day course of vancomycin rather
than a second course of metronidazole if metronidazole was used for the
primary episode (W-L).
➤ Antibiotic treatment options for patients with more than one recurrence
include (W-L):
• oral vancomycin therapy using a tapered and pulsed regimen,
• a standard course of oral vancomycin followed by rifaximin, or
• fidaxomicin.
➤ Fecal microbiota transplantation (FMT) is recommended for patients with
multiple recurrences who have failed appropriate antibiotic treatments
(S-M).
➤ There are insufficient data at this time to recommend extending the length
of anti-C. difficile treatment beyond the recommended treatment course
or restarting an anti-C. difficile agent empirically for patients who require
continued antibiotic therapy directed against the underlying infection
or who require retreatment with antibiotics shortly after completion of
treatment, respectively (NR).
Important Safety Information
DIFICID is contraindicated in pa ents with hypersensi vity to fidaxomicin.
DIFICID should not be used for systemic infec ons.
Acute hypersensi vity reac ons, including dyspnea, rash pruritus, and angioedema of the mouth,
throat, and face have been reported with fidaxomicin. If a severe hypersensi vity reac on occurs,
DIFICID should be discon nued and appropriate therapy should be ins tuted.
